...
首页> 外文期刊>Journal of infusion nursing: the official publication of the Infusion Nurses Society >Techniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled administration technique (INFUSE AT) study.
【24h】

Techniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled administration technique (INFUSE AT) study.

机译:重组人透明质酸酶促进透明质酸酶皮下输液的技术:利用皮下给药技术(INFUSE AT)研究增加流量。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Recombinant human hyaluronidase facilitates subcutaneous (SC) fluid delivery, but little is known about how various access sets influence ease of administration, technical challenges (TCs), or adverse events. METHODS: This randomized, open-label, parallel-group trial was performed to assess the impact of catheter size (20- and 24-gauge short peripheral intravenous catheter, 27-gauge SC button), catheter material (Teflon, polyurethane), and securement method (transparent semipermeable membrane dressing [TSM], double chevron with cloth or plastic tape) on hyaluronidase-facilitated SC fluid delivery. Healthy volunteers (N = 100) were randomized to 1 of 9 access groups using a factorial design. To minimize variability, treatment was performed at a single center and standardized to 150 units of SC recombinant human hyaluronidase (HYLENEX, Baxter Healthcare Corporation) followed by 1000 mL of lactated Ringer's solution. RESULTS: The first attempt at needle insertion succeeded in 98% of subjects; the median time for first catheter placement was less than 1 minute. The median infusion time was 6.8 hours. Overall, the incidence of TCs observed (catheter kinking, dislodgment, or pullout or infusion pump alarm) was low and comparable across groups (16.7%-27.3%); however, catheter kinking, dislodgment, and pullout occurred only in groups using double- chevron securement. Infusion-site reactions (pain, 20%-75%; erythema, 17%-36%; swelling, 0%-33%) were the most common adverse events. Pain was less frequent in groups using the 27-gauge SC button (27%) or the 24-gauge catheter (20%-36%) than with the 20-gauge catheter (50%-75%). DISCUSSION: Hyaluronidase-facilitated SC fluid administration with recombinant human hyaluronidase was generally well tolerated and successfully implemented using a range of access sets. Technical challenges were not common but were further minimized with TSM securement. Infusion-site pain was mostly mild and least common with 24-gauge or smaller cathetereedles.
机译:简介:重组人透明质酸酶促进皮下(SC)液体输送,但人们对各种通路如何影响给药的容易程度,技术挑战(TC)或不良事件知之甚少。方法:这项随机,开放标签,平行组的试验旨在评估导管尺寸(20和24号短径外周静脉导管,27号SC纽扣),导管材料(聚四氟乙烯,聚氨酯)和透明质酸酶促进SC液输送的固定方法(透明半透膜敷料[TSM],双V型臂和布或塑料胶带)。使用析因设计,将健康志愿者(N = 100)随机分为9个进入组中的1个。为了最大程度地减少变异性,在单个中心进行处理,并标准化为150单位的SC重组人透明质酸酶(HYLENEX,Baxter Healthcare Corporation),然后加入1000 mL乳酸林格氏液。结果:98%的受试者首次成功插入针头。首次置入导管的中位时间少于1分钟。中位输注时间为6.8小时。总体而言,观察到的TCs发生率(导管扭结,移位,拔出或输液泵警报)较低,在各组之间可比(16.7%-27.3%);但是,只有使用双重人字形固定的组才发生导管扭结,移位和拔出。最常见的不良事件是输液部位反应(疼痛,占20%-75%;红斑,占17%-36%;肿胀,占0%-33%)。与使用20号导管(50%-75%)相比,使用27号SC按钮(27%)或24号导管(20%-36%)的疼痛发生率较低。讨论:透明质酸酶促进的重组人透明质酸酶的SC液给药通常耐受性良好,并通过一系列使用途径成功实施。技术挑战并不常见,但通过TSM的保护可以进一步减少。输注部位的疼痛大多数是轻度的,而对于24号或更小的导管/针头则很少见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号